Danish allergy immunotherapy specialist ALK Abello today announced the first market launch of EURneffy (epinephrine) 2mg (the ...

An alternative to epinephrine autoinjectors that can be delivered by a nasal spray has been launched in Germany, its first ...

ALK ( ALKB:DC / OMX: ALK B) today announced the first market launch of EURneffy ® 2 mg (the trade name for neffy® in the EU) in Germany. The launch of this first ever adrenaline nasal spray for timely ...

Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to distribute multiple life-saving opioid overdose ...

Milestone Pharmaceuticals Inc. announced an investor event on February 25, 2025, in New York to discuss its commercial launch plan for etripamil nasal spray, also known as CARDAMYST™, which is ...

Inclusion of neffy on Express Scripts commercial formularies was effective November 22, 2024and expands access to patients and caregivers managing Type 1 Allergic Reactions SAN DIEGO, Dec. 19, 2024 ...

Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical group, today announces that it has entered an exclusive commercial partnership with Emergent BioSolutions (Emergent) for the ...

The nasal spray "Neffy" is the first needle-free option for severe allergic reactions that the FDA has approved. The spray would be an alternative to EpiPens.

Under the terms of the six-year agreement, Emergent will add KLOXXADO® Nasal Spray to its naloxone product portfolio and will be responsible for all North America product sales and marketing.

Alongside over-the-counter NARCAN ® Nasal Spray 4 mg, prescription KLOXXADO ® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to distribute multiple life-saving opioid overdose ...

The nasal spray "Neffy" is the first needle-free option for severe allergic reactions that the FDA has approved. The spray would be an alternative to EpiPens.

--Emergent BioSolutions Inc. announced today that it has entered into an agreement to obtain exclusive commercial rights in the U.S. and Canada to Hikma Pharmaceuticals’ KLOXXADO ® Nasal Spray ...